https://www.intelext.io/ weekly 1.0 https://www.intelext.io/about monthly 0.8 https://www.intelext.io/insights weekly 0.8 https://www.intelext.io/demo monthly 0.9 https://www.intelext.io/contact monthly 0.7 https://www.intelext.io/privacy monthly 0.6 https://www.intelext.io/terms monthly 0.6 https://www.intelext.io/dpa monthly 0.5 https://www.intelext.io/subprocessors monthly 0.5 https://www.intelext.io/impressum yearly 0.5 https://www.intelext.io/insights/fda-s-food-effect-guidance-signals-a-narrower-updated-path-for-oral-drug-development-studi-102026-08-20T08:47:11.845Z https://www.intelext.io/insights/fda-s-ich-m15-notice-puts-model-informed-evidence-into-the-harmonised-dossier-conversation-82026-08-20T08:47:11.845Z https://www.intelext.io/insights/fda-s-june-device-actions-point-to-a-practical-special-controls-workload-not-just-new-prod-42026-08-20T08:47:11.845Z https://www.intelext.io/insights/fda-puts-a-weight-loss-endoscopic-suturing-device-into-class-ii-with-special-controls-332026-08-20T08:47:11.845Z https://www.intelext.io/insights/fda-s-ai-trial-pilot-comment-extension-keeps-software-governance-on-the-policy-agenda-322026-08-20T08:47:11.845Z https://www.intelext.io/insights/ema-s-july-r-d-platform-shows-bioequivalence-policy-is-being-folded-into-a-wider-evidence--162026-08-20T08:47:11.845Z https://www.intelext.io/insights/fda-separates-psychedelic-trial-expectations-from-the-unresolved-care-model-debate-2582026-08-20T08:47:11.845Z https://www.intelext.io/insights/u-s-and-gb-device-lifecycle-controls-are-live-china-s-revised-gmp-starts-november-1-2612026-08-03T08:26:26.107Z https://www.intelext.io/insights/ema-and-mhra-raise-the-design-bar-for-real-world-external-controls-2732026-08-11T11:20:40.029Z https://www.intelext.io/insights/eu-opens-injectable-iron-review-over-hypophosphataemia-and-bone-disorders-2852026-09-08T14:17:25.458Z